Market News AIOpen the app

Oric Pharmaceuticals, Inc. shares new information about its drug trial and plans to start a bigger study in 2027.

TrialRead the original at SEC EDGAR
Good for ORIC

Oric’s Phase 1b study found tumor shrinkage in many patients, including those with brain tumors. It included 26 patients, and lasting benefit is not yet known, but the results favor the drug’s prospects.

ORIC · Oric Pharmaceuticals, Inc.

AI read · Good for ORIC

The AI's read

The results give Oric evidence that enozertinib may shrink tumors, including in the brain. The study included only 26 patients, and lasting benefit is not yet known. A much larger trial is planned, so success remains unproven.

Get alerts for ORIC

Follow Oric Pharmaceuticals, Inc. (ORIC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ORIC
Free on the App Store and Google Play, or on the web.